KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
15.79
0.00 (0.00%)
At close: Dec 24, 2025, 4:00 PM EST
15.99
+0.20 (1.27%)
Pre-market: Dec 26, 2025, 4:06 AM EST
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 270 employees as of April 30, 2025. The number of employees increased by 120 or 80.00% compared to the previous year.
Employees
270
Change (1Y)
120
Growth (1Y)
80.00%
Revenue / Employee
$5,281
Profits / Employee
-$752,211
Market Cap
798.13M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 270 | 120 | 80.00% |
| Apr 30, 2024 | 150 | 32 | 27.12% |
| Apr 30, 2023 | 118 | 13 | 12.38% |
| Apr 30, 2022 | 105 | 35 | 50.00% |
| Apr 30, 2021 | 70 | 14 | 25.00% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KALV News
- 3 days ago - KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - Business Wire
- 2 months ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Business Wire